 Biolase Inc NASDAQ: BIOL reported a Q1 EPS loss of 0.06, which missed the analyst consensus of 0.05 loss, though it improved from a loss of 0.19 reported a year ago. Net revenue of 8.1 million beat the analyst consensus of 7.79 million and increase 70 YY as Q1 2020 was impacted by the COVID-19 pandemic. 